Physician profile
Michael J Thomas
NPI 1578514600
$3,751.95
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,118 · 2022: $1,291 · 2023: $1,054 · 2024: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,343.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $649.71 | 2021-2024 | |
| Collegium Pharmaceutical, INC. | $424.00 | 2021-2023 | Xtampza |
| Novo Nordisk INC | $348.86 | 2022-2023 | |
| Abbott Laboratories | $273.37 | 2021-2023 | Eterna, Proclaim |
| Boston Scientific Corporation | $259.54 | 2021-2023 | Wavewriter Alpha Prime 16 |
| Atricure, INC. | $196.93 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $160.95 | 2021 | |
| Vertos Medical, INC. | $144.82 | 2021 | |
| Medtronic, INC. | $134.82 | 2021-2023 | Venaseal |
| Biohaven Pharmaceutical Holding Company LTD. | $131.48 | 2022 | |
| Nevro Corp. | $117.90 | 2021-2022 | |
| Foundation Fusion Solutions, LLC | $115.81 | 2024 | |
| Stimwave Technologies Incorporated | $111.81 | 2021-2022 | |
| Tersera Therapeutics LLC | $104.11 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $79.42 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $61.39 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.58 | 2021-2023 | Relistor |
| Curonix LLC | $42.85 | 2022-2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Adaptive Biotechnologies Corporation | $40.57 | 2024 | Clonoseq |
| Almatica Pharma LLC | $35.26 | 2022-2023 | Gralise |
| Biodelivery Sciences International, INC. | $33.32 | 2021 | |
| Pfizer INC. | $33.06 | 2023 | |
| Relievant Medsystems, INC. | $32.31 | 2021-2022 | |
| Lilly USA, LLC | $28.95 | 2021 | |
| Radius Health, INC. | $27.34 | 2021 | |
| Indivior INC. | $27.08 | 2024 | Sublocade |
| Amgen INC. | $24.21 | 2021-2022 | |
| Alkermes, INC. | $18.06 | 2023 | Vivitrol |
| West Therapeutics Development, LLC | $14.29 | 2021 | |
| Grt US Holding, INC. | $13.72 | 2021 | |
| Pacira Therapeutics, INC. | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.